MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
10.42
-0.17
-1.56%
Opening 14:21 12/26 EST
OPEN
10.54
PREV CLOSE
10.58
HIGH
10.66
LOW
10.31
VOLUME
94.77K
TURNOVER
--
52 WEEK HIGH
18.76
52 WEEK LOW
4.930
MARKET CAP
398.05M
P/E (TTM)
-4.1603
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRDA last week (1215-1219)?
Weekly Report · 4d ago
Entrada Therapeutics CEO to Present at J.P. Morgan Healthcare Conference
Reuters · 12/17 12:00
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16 14:19
Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs
Reuters · 12/15 17:45
Weekly Report: what happened at TRDA last week (1208-1212)?
Weekly Report · 12/15 09:19
Weekly Report: what happened at TRDA last week (1201-1205)?
Weekly Report · 12/08 09:18
Entrada Therapeutics Grants Stock Options and RSUs to New Employees Under 2025 Inducement Plan
Reuters · 12/04 21:30
ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/04 21:30
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.